| Literature DB >> 22373530 |
Barbara Kraus1, Simone von Fircks1, Simone Feigl1, Sabrina M Koch1, Daniel Fleischanderl1, Katherine Terler1, Mitra Dersch-Pourmojib1, Christian Konetschny1, Leopold Grillberger1, Manfred Reiter1.
Abstract
Entities:
Year: 2011 PMID: 22373530 PMCID: PMC3285011 DOI: 10.1186/1753-6561-5-S8-P52
Source DB: PubMed Journal: BMC Proc ISSN: 1753-6561
Figure 1Schematic overview of the cell line history
List of guidelines according to which the avian cell line was tested
| Organization | Number | Title |
|---|---|---|
| European Pharmacopoeia. (EP) 2.6.16. | Tests for extraneous agents in viral vaccines for human use | |
| EP 5.2.3. | Cell substrates for the production of vaccines for human use | |
| Q5A (R1)-1999 | Viral safety evaluation of biotechnology products derived from cell lines of human of animal origin | |
| Q5D-1997 | Derivation and characterization of cell substrates used for production of biotechnological/biological products | |
| Q7A-2000 | Good manufacturing practice guide for active pharmaceutical ingredients | |
| ---- | Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1993) | |
| ---- | Guidance for Industry, Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indication (February 2010) | |
| 9CFR113.47 | Detection of extraneous agents viruses by fluorescent antibody technique | |
| 21CFR610.18 | General biological products standards | |
Figure 2Growth Kinetics of rMVA viruses on QOR2/2E11